(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt

Modify Date: 2024-01-02 17:46:31

(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt structure	Common Name	(Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt
	CAS Number	90779-69-4	Molecular Weight	994.189
	Density	1.3±0.1 g/cm3	Boiling Point	1469.0±65.0 °C at 760 mmHg
	Molecular Formula	C₄₃H₆₇N₁₁O₁₂S₂	Melting Point	N/A
	MSDS	Chinese USA	Flash Point	842.2±34.3 °C

Use of (Deamino-Cys1,D-Tyr(Et)2,Thr4,Orn8)-Oxytocin acetate salt

Atosiban(RW22164; Tractocile) is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane.IC50 value:Target: As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.[1][2] In human pre-term labour, atosiban, at the recommended dosage, antagonises uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Name	Atosiban
Synonym	More Synonyms

Description	Atosiban(RW22164; Tractocile) is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane.IC50 value:Target: As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.[1][2] In human pre-term labour, atosiban, at the recommended dosage, antagonises uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Oxytocin Receptor Research Areas >> Others
References	[1]. Sanu O, et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9. [2]. Akerlund M, et al. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin. Acta Obstet Gynecol Scand. 1985;64(6):499-504.

Description

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Oxytocin Receptor

Research Areas >> Others

References

[1]. Sanu O, et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9.

[2]. Akerlund M, et al. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin. Acta Obstet Gynecol Scand. 1985;64(6):499-504.

Density	1.3±0.1 g/cm3
Boiling Point	1469.0±65.0 °C at 760 mmHg
Molecular Formula	C₄₃H₆₇N₁₁O₁₂S₂
Molecular Weight	994.189
Flash Point	842.2±34.3 °C
Exact Mass	993.441223
PSA	416.27000
LogP	-3.41
Vapour Pressure	0.0±0.3 mmHg at 25°C
Index of Refraction	1.549
Storage condition	−20°C
Water Solubility	H2O: ≤100 mg/mL

MSDS(Chinese)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: RS7590000

CHEMICAL NAME :: Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornith ine

CAS REGISTRY NUMBER :: 90779-69-4

LAST UPDATED :: 198912

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C43-H67-N11-O12-S2

MOLECULAR WEIGHT :: 994.33

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 94 ug/kg

SEX/DURATION :: female 1-35 week(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects

REFERENCE :: BJOGAS British Journal of Obstetrics and Gynaecology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.82- 1975- Volume(issue)/page/year: 94,1040,1987

RIDADR	NONH for all modes of transport
RTECS	RS7590000

Reversal of peripheral nerve injury-induced hypersensitivity in the postpartum period: role of spinal oxytocin.

Anesthesiology 118(1) , 152-9, (2013)

Physical injury, including surgery, can result in chronic pain; yet chronic pain following childbirth, including cesarean delivery in women, is rare. The mechanisms involved in this protection by preg...

Development and clinical experience with the new evidence-based tocolytic atosiban.

Acta Obstet. Gynecol. Scand. 81(7) , 633-41, (2002)

The incidence of preterm birth has remained unchanged for the last few decades. This is due, in part, to the complex etiology of preterm labor, and the limited ability of tocolytic agents to prolong p...

Oxytocin regulates changes of extracellular glutamate and GABA levels induced by methamphetamine in the mouse brain.

Addict. Biol. 17(4) , 758-69, (2012)

Oxytocin (OT), a neurohypophyseal neuropeptide, affects adaptive processes of the central nervous system. In the present study, we investigated the effects of OT on extracellular levels of glutamate (...

1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin

MFCD00672436

antocin

ATOSIBAN ACETATE

oxytocin,1-(3-mercaptopropanoicacid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l

1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin

1-deamino-2d-tyr-(oet)-4-thr-8-orn-oxytocin

Tractocile

1-({(4R,7S,10S,13S,16R)-7-(2-Amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide

1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineoxytocin

Atosiban

Glycinamide, 1-[[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]-L-prolyl-L-ornithyl-

[Mpr-D-Tyr(OEt)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2

1-({(4R,7S,10S,13S,16R)-7-(2-Amino-2-oxoethyl)-13-[(2S)-2-butanyl]-16-(4-ethoxybenzyl)-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-ornithylglycinamide